Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301)

Gastric Cancer Clinical Trial

Official title:

Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer Stage II Randomized Controlled Clinical Studies

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02596256
• Other study ID #: AHEAD-301
• Status: Active, not recruiting
• Phase: Phase 2
• First received: November 2, 2015
• Last updated: April 13, 2018
• Start date: April 2016
• Est. completion date: February 2019

Study information

• Verified date: April 2018
• Source: Chinese PLA General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Apatinib plus docetaxel versus docetaxel as second-line treatment in advanced gastric cancer.

Description:

This trial investigated the safety and efficacy of apatinib plus docetaxel, as a treatment option for heavily pretreated patients with advanced gastric cancer.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 80
• Est. completion date: February 2019
• Est. primary completion date: February 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age: more than 18 years old, male or female;

2. Pathologically diagnosed with advanced gastric cancer (including adenocarcinoma of the gastroesophageal junction) with measurable metastases outside the stomach (measuring = 10mm on spiral computed tomography(CT) scan, satisfying the criteria in Response Evaluation Criteria In Solid Tumors (RECIST) 1.1);

3. Failure of prior therapy (during or after treatment) in patients who have received at first line chemotherapy regimens(platinum - based regimens);

4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1;

5. Major organ function has to meet the following criteria; (1) For results of blood routine test and biochemical tests:

1. Hemoglobin (HB) = 80g / L,

2. ANC = 1.5 × 109 / L,

3. PLT = 90 × 109 / L,

4. ALT and AST = 2.5 × ULN, liver metastases, if any, the ALT and AST=5 × ULN,

5. Bilirubin = 1.5 times the upper limit of normal (ULN),

6. Serum creatinine = 1.5 times the upper limit of normal (ULN),

7. Serum albumin = 30g / L;

6. An expected survival of = 3 months;

7. Pregnancy test (serum or urine) has to be performed for woman of childbearing age within 7 days before enrolment and the test result must be negative. They shall take appropriate methods for contraception during the study until the 8th week post the last administration of study drug. For men, (previous surgical sterilization accepted), shall agree to take appropriate methods of contraception during the study until the 8th week post the last administration of study drug;

8. Patient has to voluntarily join the study and sign the Informed Consent Form for the study.

Exclusion Criteria:

1. Confirmed that apatinib and/or its accessories allergy;

2. Subjects with poor-controlled arterial hypertension (systolic blood pressure> 140 mmHg and diastolic blood pressure > 90 mm Hg) despite standard medical management; Coronary heart disease greater than Class ?; ?-level arrhythmia (including QT interval prolongation, for man = 450 ms, for woman = 470 ms) together with Class ? cardiac dysfunction; Patients with positive urinary protein;

3. Factors that could have an effect on oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction);

4. Subjects with high gastrointestinal bleeding risk, including the following conditions:

local active ulcer lesions with positive fecal occult blood test (++); history of black stool, or vomiting blood in the past 2 months;unresected primary lesion in stomach with positive fecal occult blood test (+), ulcerated gastric carcinoma with massive alimentary tract bleeding risk judged by PIs based on gastric endoscopy result;

5. Abnormal Coagulation (INR>1.5?APTT>1.5 UNL), with tendency of bleed;

6. Associated with CNS (central nervous system) metastases;

7. Pregnant or lactating women;

8. Pts with other malignant tumor within 5 years;

9. With psychotropic drug abuse history and can't get rid of or mental disorder patients;

10. Participated in other clinical trials within 4 weeks;

11. Pts received VEGFR inhibitor treatment(i.e. sorafenib, sunitinib);

12. Any other condition that might place the patient at undue risk or preclude a patient from completing the study;

13. Other conditions regimented at investigators' discretion.

Related Conditions & MeSH terms

• Gastric Cancer
• Stomach Neoplasms

Intervention

Drug:
• Apatinib
Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity
• Docetaxel
Docetaxel (60 mg/m2 qd d1 q3w i.v.) until disease progression or intolerable toxicity

Locations

Country	Name	City	State
China	Chinese PLA General Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Chinese PLA General Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression free survival		6 months